XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments and Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table presents the Company’s fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis (in thousands):

 

 

September 30, 2021

 

 

December 31, 2020

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

 

 

$

 

 

$

 

 

$

 

 

$

 

 

$

 

Derivative financial instruments

 

 

 

 

 

2

 

 

 

 

 

 

 

 

 

1

 

 

 

 

Investment in Albertsons (Note 4)

 

 

128,186

 

 

 

 

 

 

 

 

 

72,391

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative financial instruments

 

 

 

 

 

54,827

 

 

 

 

 

 

 

 

 

90,139

 

 

 

 

Schedule of Items Measured at Fair Value on Nonrecurring Basis

During 2020 and 2021, the Company was impacted by the COVID-19 Pandemic (Note 11), which caused the Company to reduce its holding periods and forecasted operating income at certain properties. As a result, several impairments were recorded. Impairment charges for the periods presented are as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

Impairment Charge

 

Property and Location

 

Owner

 

Triggering Event

 

Level 3 Inputs

 

Effective Date

 

Total

 

 

Acadia's Share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2021 Impairment Charges

 

 

 

 

 

 

 

 

 

 

 

 

 

 

210 Bowery,
Manhattan, NY

 

Fund IV

 

Reduced projected operating income

 

Projections of: holding period, net operating income, cap rate, incremental costs

 

Sept 30, 2021

 

$

3,016

 

 

$

697

 

27 E. 61st Street
Manhattan, NY

 

Fund IV

 

Reduced projected operating income

 

Projections of: holding period, net operating income, cap rate, incremental costs

 

Sept 30, 2021

 

 

6,909

 

 

 

1,597

 

Total 2021 Impairment Charges

 

 

 

 

 

 

 

 

 

$

9,925

 

 

$

2,294

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2020 Impairment Charges

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cortlandt Crossing,
Mohegan Lake, NY

 

Fund III

 

Reduced holding period, reduced projected operating income

 

Projections of: holding period, net operating income, cap rate, incremental costs

 

Mar 31, 2020

 

$

27,402

 

 

$

6,726

 

654 Broadway,
New York, NY

 

Fund III

 

Reduced holding period

 

Projections of: holding period, net operating income, cap rate, incremental costs

 

Mar 31, 2020

 

 

6,398

 

 

 

1,570

 

146 Geary Street,
San Francisco, CA

 

Fund IV

 

Reduced holding period, reduced projected operating income

 

Projections of: holding period, net operating

 

Mar 31, 2020

 

 

6,718

 

 

 

1,553

 

 

 

 

 

 

 

 

income, cap rate, incremental costs

 

 

 

 

 

 

 

 

 

 

801 Madison Avenue,
New York, NY

 

Fund IV

 

Reduced holding period, reduced projected operating income

 

Projections of: holding period, net operating income, cap rate, incremental costs

 

Mar 31, 2020

 

 

11,031

 

 

 

2,551

 

717 N. Michigan Avenue,
Chicago, IL

 

Fund IV

 

Reduced holding period, reduced projected operating income

 

Projections of: holding period, net operating income, cap rate, incremental costs

 

Dec 31, 2020

 

 

17,392

 

 

 

4,021

 

110 University,
New York, NY

 

Fund IV

 

Reduced holding period, reduced projected operating income

 

Projections of: holding period, net operating income, cap rate, incremental costs

 

Dec 31, 2020

 

 

16,238

 

 

 

3,754

 

Fifth Wall Investment

 

Core

 

Decline in fair value

 

Projections of: reported fair value of net assets

 

Dec 31, 2020

 

 

419

 

 

 

419

 

Total 2020 Impairment Charges

 

 

 

 

 

 

 

 

 

$

85,598

 

 

$

20,594

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Schedule of Derivative Financial Instruments

The Company had the following interest rate swaps and caps for the periods presented (dollars in thousands):

 

 

 

 

 

 

 

 

 

 

Strike Rate

 

 

 

 

Fair Value

 

Derivative
Instrument

 

Aggregate Notional Amount

 

 

Effective Date

 

Maturity Date

 

Low

 

 

 

High

 

 

Balance Sheet
Location

 

September 30,
2021

 

 

December 31,
2020

 

Core

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest Rate Swaps

 

$

539,636

 

 

Dec 2012-Jul 2020

 

Mar 2022-Jul 2030

 

 

1.71

%

 

 

 

3.77

%

 

Other Liabilities

 

$

(46,731

)

 

$

(74,990

)

 

 

$

539,636

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

(46,731

)

 

$

(74,990

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fund II

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest Rate Swap

 

$

18,588

 

 

Oct 2014

 

Nov 2021

 

 

1.49

%

 

 

 

1.49

%

 

Other Liabilities

 

$

(23

)

 

$

(219

)

Interest Rate Cap

 

 

45,000

 

 

Mar 2019

 

Mar 2022

 

 

3.50

%

 

 

 

3.50

%

 

Other Assets

 

 

 

 

 

 

 

 

$

63,588

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

(23

)

 

$

(219

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fund III

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest Rate Caps

 

$

35,970

 

 

Jan 2021

 

Jul 2022

 

 

3.00

%

 

 

 

3.00

%

 

Other Assets

 

$

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fund IV

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest Rate Swaps

 

$

42,385

 

 

Mar 2017-Dec 2019

 

Apr 2022-Dec 2022

 

 

1.48

%

 

 

 

2.61

%

 

Other Liabilities

 

$

(528

)

 

$

(1,713

)

Interest Rate Caps

 

 

71,338

 

 

Dec 2020 - Jul 2021

 

Dec 2022-Jul 2023

 

 

3.00

%

 

 

 

3.50

%

 

Other Assets

 

 

2

 

 

 

1

 

 

 

$

113,723

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

(526

)

 

$

(1,712

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fund V

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest Rate Swaps

 

$

298,014

 

 

Jun 2018-Feb 2021

 

Feb 2022-Oct 2024

 

 

0.23

%

 

 

 

2.88

%

 

Other Liabilities

 

$

(7,545

)

 

$

(13,217

)

 

 

$

298,014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

(7,545

)

 

$

(13,217

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total asset derivatives

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

2

 

 

$

1

 

Total liability derivatives

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

(54,827

)

 

$

(90,139

)

Schedule of Other Financial Instruments Carrying Values and Fair values

The Company’s other financial instruments had the following carrying values and fair values as of the dates shown (dollars in thousands, inclusive of amounts attributable to noncontrolling interests where applicable):

 

 

 

 

 

 

September 30, 2021

 

 

December 31, 2020

 

 

 

Level

 

 

Carrying
Amount

 

 

Estimated
Fair Value

 

 

Carrying
Amount

 

 

Estimated
Fair Value

 

Notes Receivable (a)

 

 

3

 

 

$

158,468

 

 

$

159,476

 

 

$

101,450

 

 

$

102,135

 

Mortgage and Other Notes Payable (a)

 

 

3

 

 

 

1,185,228

 

 

 

1,165,716

 

 

 

1,210,540

 

 

 

1,190,214

 

Investment in non-traded equity securities (b)

 

 

3

 

 

 

3,021

 

 

 

3,772

 

 

 

1,726

 

 

 

1,456

 

Unsecured notes payable and Unsecured line of credit (c)

 

 

2

 

 

 

610,981

 

 

 

616,056

 

 

 

559,514

 

 

 

544,532

 

 

 

(a)
The Company determined the estimated fair value of these financial instruments using a discounted cash flow model with rates that take into account the credit of the borrower or tenant, where applicable, and interest rate risk. The Company also considered the value of the underlying collateral, taking into account the quality of the collateral, the credit quality of the borrower, the time until maturity and the current market interest rate environment.
(b)
Represents the Operating Partnership’s cost-method investment in Fifth Wall (Note 4).
(c)
The Company determined the estimated fair value of the unsecured notes payable and unsecured line of credit using quoted market prices in an open market with limited trading volume where available. In cases where there was no trading volume, the Company determined the estimated fair value using a discounted cash flow model using a rate that reflects the average yield of similar market participants.